



11th August, 2021

To,
The Manager,
Listing & Compliance,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001.

Ref: Scrip Code - 506405

Sub: Investor Presentation for Q1FY22.

Dear Sir/Madam,

Pursuant to Regulation 30(6) of the SEBI (Listing Obligation and Disclosure Requirements) Regulation 2015, we are enclosing herewith Investor Presentation on the Company's Financial Performance of Q1FY22.

The said presentation is also being made available at the website of the Company at www.dmcc.com

You are requested to kindly take the same on your record.

Thanking you,

For The Dharamsi Morarji Chemical Company Ltd.,

Omkar C. Mhamunkar
Company Secretary & Compliance Officer
Membership No. ACS 26645

Encl : As above

CIN NUMBER: L24110MH1919PLC000564

Earnings Presentation

Q1FY22 EARNINGS PRESENTATION
(August 2021)

BSE – DHARAMSI | 506405

Bloomberg – DMCC:IN

The Dharamsi Morarji Chemical Co. Limited

100 + years of expertise in Sulphur Chemistry



THE DHARAMSI MORARJI CHEMICAL CO. LTD.



TOGETHER FOR
SUSTAINABILITY



Responsible Care®
OUR COMMITMENT TO SUSTAINABILITY

DMCC

Safe Harbour

This investor presentation has been prepared by Dharamsi Morarji Chemicals Company Limited (“DMCC”) and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be deemed to constitute an offer. No representation or warranty, express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be “forward looking statements”, including those relating to the general business plans and strategy of DMCC, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as ‘will’, ‘expected to’, ‘horizons of growth’, ‘strong growth prospects’, etc., or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements. These risks and uncertainties include, but are not limited to risks with respect to its hair care, its healthcare business and its skin care business. DMCC may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.

QUARTERLY UPDATES

MANAGEMENT REMARKS

UPDATES ON CAPEX

CONTACT US

Inside the
document

To view our **corporate film**
Visit: <https://bit.ly/3ePHS7S>
or Scan the QR code.



Financial Statement Summary

CONSOLIDATED P&L STATEMENT

Figures in INR Crores

PARTICULARS	Q1 FY22	Q4 FY21	Q1 FY21
Revenue from Operations	70.65	63.89	39.16
Total Income	72.46	64.28	39.53
Total Operating Expense	59.66	53.50	31.42
EBITDA	12.79	10.79	8.11
EBITDA Margins %	18.11%	16.89%	20.72%
Interest Cost	0.49	0.37	0.42
Depreciation and Amortisation	1.79	1.76	1.64
Profit Before Taxes	10.51	8.65	6.05
Profit After Taxes	7.52	10.76 *	5.43

CLICK HERE to view the financial results- <https://www.bseindia.com/xml-data/corpfiling/AttachLive/d2f607da-7a18-4781-82ce-1743422f67b1.pdf>

Y-o-Y

80.39% ▲

Q1FY22 Revenue from Operations at INR 70.65 crores as compared to INR 63.89 crores in Q1FY21

57.69% ▲

Q1FY22 EBITDA at INR 12.79 crores as compared to INR 8.11 crores in Q1FY21

73.75% ▲

Q1FY22 PBT at INR 10.51 crores as compared to INR 6.05 crores in Q1FY21

38.50% ▲

Q1FY22 Profit After Tax at INR 7.52 crores as compared to INR 5.43 crores in Q1FY21.

Q-o-Q

10.58% ▲

Q1FY22 Revenue from Operations at INR 70.65 crores as compared to INR 63.89 crores in Q4FY21

18.61% ▲

Q1FY22 EBITDA at INR 12.79 crores as compared to INR 10.79 crores in Q4FY21

21.49% ▲

Q1FY22 PBT at INR 10.51 crores as compared to INR 8.65 crores in Q4FY21

30.13% ▼

Q1FY22 Profit After Tax at INR 7.52 crores as compared to INR 10.76 crores in Q4FY21.

* Q4FY21 PAT is inclusive of MAT credit entitlement of INR 4.62 crores

Management Remarks

FINANCIAL PERFORMANCE:

The Company recorded a strong financial performance in Q1FY22 as the revenues increased by 10.58% to IN 70.65 crores as against INR 63.89 crores in Q4FY21. The performance is attributable to higher volumes and realisations across products in bulk and speciality chemicals segment.

The export and domestic markets continued to perform well and as a result, the Company recorded a 18.61% and 21.49% growth in EBITDA and PBT respectively on a Q-o-Q basis.

SEGMENT PERFORMANCE:

- The company recorded strong performance in speciality chemicals segment despite the challenges faced during the 2nd wave of Covid-19. There is strong visibility and order book for the existing and planned capacities. This segment should continue to perform well going forward.
- The commodity segment of the boron business continued to face a challenging environment with availability of raw materials being a roadblock. However the company continues to witness traction on the specialty part of the boron business.
- The company recorded a steady performance in the bulk chemicals segment. With the commissioning of bulk chemicals plant at Dahej towards the end of Q2FY22, the Company remains confident of delivering a strong performance in this segment going forward.

OPERATING ENVIRONMENT:

The raw material prices continue to be on an upswing. However, the price increase will be passed on to the consumer with a lag of a quarter.

The freight and logistics cost continue to escalate. This will also be passed on to the consumer, however, with a lag of a quarter.

PARTICULARS	Q1FY22	Q4FY21
Export sales	28%	29%
Domestic sales	72%	71%

PARTICULARS	Q1 FY22	Q4 FY21
Sale of specialty chemicals including exports	55%	64%
Sale of bulk chemicals	41%	35%
Other Operating Income	4%	1%

Update on Capex

Debottlenecking at Roha	Multipurpose plants at Dahej	Bulk chemicals at Dahej	Specialty chemicals at Dahej	Intermediates Plant at Dahej
<p>The company is progressing well on its plans of debottlenecking at the Roha facility. The company will invest ~ INR 10 crores on this project.</p>	<p>The company invested INR 10 crores in 2 multipurpose plants at the Dahej facility.</p>	<p>The company will be investing INR 50 crores in adding incremental capacity in bulk chemicals segment.</p>	<p>The company will invest INR 20 Crores in a dedicated plant at Dahej facility.</p>	<p>The company had plans to invest INR 20 crores for expansion to manufacture intermediates for pharmaceutical and agrochemical industry.</p>
<p>In process of commissioning</p>	<p>Complete</p>	<p>The company has been facing certain challenges in terms of delays from vendors, however the company is on track to complete the project by September 2021</p>	<p>The company will use this facility for contract manufacturing. The products to be manufactured and other details remain confidential as the company has signed an NDA.</p>	<p>This project is expected to complete by March 22</p>
<p>This will start contributing to the financial performance from Q2FY22</p>	<p>This will start contributing to the financial performance from Q2FY22</p>		<p>The plant is expected to begin commercial production by December 2021</p>	<p>The company had earlier decided to invest this amount in Sulfones. However with a downturn in the international markets for the product category, the plan has been put on hold</p>

Get in Touch

MR. OMKAR MHAMUNKAR

*Company Secretary and Compliance
Officer*

The Dharamsi Morarji Chemical Co.
Limited

omhamunkar@dmcc.com



MR. ABHISHEK MEHRA

Investor Relations Advisor

The Investment Lab

abhishek@theinvestmentlab.in

